Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13
Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Genentech Inc, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17
Partnerships 18
Microbiotica Enters into Collaboration Agreement with Genentech 18
Tesaro Enters into Collaboration Agreement with Genentech 19
Lodo Therapeutics Enters into Agreement with Genentech 20
Tesaro Enters into Partnership with Genentech 21
Forty Seven Enters into Agreement with Genentech 22
Syndax Pharma Enters into Agreement with Genentech 23
DiCE Molecules Enters into Research Agreement with Genentech 24
Biothera Pharma Enters into Collaboration Agreement with Genentech 25
Epizyme Enters into Agreement with Genentech 26
Inovio Pharma Enters into Agreement with Genentech 27
Amunix Operating Enters into R&D Agreement with Genentech 28
BioNTech Enters into Agreement with Genentech 29
Gradalis Enters into Agreement with Genentech 30
G1 Therapeutics Enters into Agreement with Genentech 31
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 32
Charles River Laboratories International Extends Agreement with Genentech 33
BioLineRx Enters into Agreement with Genentech 34
Epizyme Enters into Agreement with Genentech 35
Astex Pharma Enters into Agreement with Genentech 36
Clovis Oncology Enters into Agreement with Genentech 37
Janssen Research & Development Enters into Agreement with Genentech 38
Kite Pharma Enters into Agreement with Genentech 39
PeptiDream Enters into Agreement with Genentech 40
Corvus Pharma Expands its Agreement with Genentech 41
Immune Design Enters into Clinical Trial Collaboration with Genentech 42
WaferGen Bio-systems Enters into Research Agreement with Genentech 43
23andMe Partners with Genentech 44
Genentech Enters into Research Agreement with NewLink Genetics 45
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 46
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 47
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 48
Constellation Pharma Enters Into Co-Development Agreement With Genentech 49
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 50
Licensing Agreements 51
Genentech Enters into Licensing Agreement with Kineta Chronic Pain 51
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 52
Mylan Enters into Licensing Agreement with Genentech and Roche 54
Genentech Enters into Licensing Agreement with Novimmune 55
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 56
Genentech to Enter into Licensing Agreement with Hanmi Pharma 57
Denali Therapeutics Enters Into Licensing Agreement With Genentech 58
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 59
Genentech Expands Licensing Agreement with Arvinas 60
Genentech Enters into Licensing Agreement with Almac Discovery 61
Phylogica Extends Licensing Agreement with Genentech 62
Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 63
Coherus BioSciences Enters into Licensing Agreement with Genentech 65
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 66
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 67
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 68
Genentech Enters into Licensing Agreement with Carmot Therapeutics 69
Afraxis Enters Into Licensing Agreement With Genentech 70
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 71
Acquisition 73
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 73
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 74
Genentech Inc – Key Competitors 75
Genentech Inc – Key Employees 76
Genentech Inc – Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Recent Developments 78
Legal and Regulatory 78
Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 78
Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 79
Government and Public Interest 80
May 14, 2018: Pivotal Study Validates Real-World Mortality Endpoint for Oncology Research 80
Jun 29, 2017: Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury 81
Product News 82
Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 82
06/15/2017: NICE reverses provisional decision and recommends Kadcyla (trastuzumab emtansine) for HER2-positive advanced breast cancer in England 84
06/12/2017: T-DM1 in HER2 Overexpressing, Amplified or Mutated Metastatic NSCLC 85
Product Approvals 87
Jun 15, 2017: Kadcyla new deal for breast cancer patients given green light in final draft guidance 87
Apr 10, 2017: Roche’s Kadcyla accepted for use in NHS Scotland 88
Clinical Trials 89
Apr 15, 2018: Genentech to Present Data on Investigational Anti-amyloid beta Antibodie Crenezumab 89
Dec 10, 2017: Phase II Data Showed Genentech’s Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma 90
Nov 30, 2017: Symphogen Receives Milestone Payment for Initiation of Phase 1b Trial in Infectious Disease 92
Nov 01, 2017: Data To Be Presented On Polatuzumab Vedotin At ASH 2017 Annual Meeting 93
Oct 24, 2017: AC Immune to Provide Scientific Update on Crenezumab at CTAD Conference 94
May 17, 2017: Data from Clinical Study of NewLink Genetics’ Navoximod to Be Presented at ASCO 2017 95
Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 96
Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer’s Therapy Crenezumab 97
Other Significant Developments 98
Feb 05, 2018: Inside Rx Provides Savings on Influenza Medications 98
Appendix 99
Methodology 99
About GlobalData 99
Contact Us 99
Disclaimer 99
Genentech Inc, Pharmaceuticals & Healthcare, Key Facts 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Genentech Inc, Deals By Therapy Area, 2012 to YTD 2018 11
Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13
Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17
Microbiotica Enters into Collaboration Agreement with Genentech 18
Tesaro Enters into Collaboration Agreement with Genentech 19
Lodo Therapeutics Enters into Agreement with Genentech 20
Tesaro Enters into Partnership with Genentech 21
Forty Seven Enters into Agreement with Genentech 22
Syndax Pharma Enters into Agreement with Genentech 23
DiCE Molecules Enters into Research Agreement with Genentech 24
Biothera Pharma Enters into Collaboration Agreement with Genentech 25
Epizyme Enters into Agreement with Genentech 26
Inovio Pharma Enters into Agreement with Genentech 27
Amunix Operating Enters into R&D Agreement with Genentech 28
BioNTech Enters into Agreement with Genentech 29
Gradalis Enters into Agreement with Genentech 30
G1 Therapeutics Enters into Agreement with Genentech 31
Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 32
Charles River Laboratories International Extends Agreement with Genentech 33
BioLineRx Enters into Agreement with Genentech 34
Epizyme Enters into Agreement with Genentech 35
Astex Pharma Enters into Agreement with Genentech 36
Clovis Oncology Enters into Agreement with Genentech 37
Janssen Research & Development Enters into Agreement with Genentech 38
Kite Pharma Enters into Agreement with Genentech 39
PeptiDream Enters into Agreement with Genentech 40
Corvus Pharma Expands its Agreement with Genentech 41
Immune Design Enters into Clinical Trial Collaboration with Genentech 42
WaferGen Bio-systems Enters into Research Agreement with Genentech 43
23andMe Partners with Genentech 44
Genentech Enters into Research Agreement with NewLink Genetics 45
Ascendis Pharma Enters Into Collaboration Agreement with Genentech 46
RQx Pharma Enters Into Drug Discovery Agreement With Genentech 47
Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 48
Constellation Pharma Enters Into Co-Development Agreement With Genentech 49
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 50
Genentech Enters into Licensing Agreement with Kineta Chronic Pain 51
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 52
Mylan Enters into Licensing Agreement with Genentech and Roche 54
Genentech Enters into Licensing Agreement with Novimmune 55
Novogen Enters into Licensing Agreement with Genentech for GDC-0084 56
Genentech to Enter into Licensing Agreement with Hanmi Pharma 57
Denali Therapeutics Enters Into Licensing Agreement With Genentech 58
Genentech Enters into Licensing Agreement with Nimbus Therapeutics 59
Genentech Expands Licensing Agreement with Arvinas 60
Genentech Enters into Licensing Agreement with Almac Discovery 61
Phylogica Extends Licensing Agreement with Genentech 62
Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 63
Coherus BioSciences Enters into Licensing Agreement with Genentech 65
Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 66
Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 67
Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 68
Genentech Enters into Licensing Agreement with Carmot Therapeutics 69
Afraxis Enters Into Licensing Agreement With Genentech 70
AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 71
Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 73
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 74
Genentech Inc, Key Competitors 75
Genentech Inc, Key Employees 76
Genentech Inc, Other Locations 77
List of Figures
Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13